Biogen Message Board - Msg: 34097339

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biogen

BIIB 179.89

+2.1%

Jan 30 9:30 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 PreviousNext

From: Sr K	11/29/2022 8:16:59 PM
	of 1686

Updated 7:50 PM Re: BIIB Researchers released new details from a study of a closely watched drug for Alzheimer’s disease on Tuesday, shedding more light on the drug’s risks and benefits as U.S. health regulators weigh approving it. Eisai Co. and Biogen Inc.’s drug, called lecanemab, slowed cognitive decline by 27% compared with a placebo over 18 months in a study of more than 1,700 people with early-stage Alzheimer’s, researchers reported in the New England Journal of Medicine on Tuesday. Exc. More In September, Biogen and partner Eisai announced positive top-line data from Clarity AD study, which showed that treatment with lecanemab exhibited statistically significant reduction of clinical decline in AD patients. The study met the primary endpoint as well as all key secondary endpoints. If approved by the FDA, the drug will be the only anti-amyloid beta antibody that can be used to treat early AD without the need for titration.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 PreviousNext